This is a research study to find out if a smoking cessation medication, varenicline, is effective when given to smokers, remotely, as a one-time, 4-week sample.
Participants will either receive a sample of varenicline, or not. This will be decided randomly. The medicine will be mailed to participants and participants will complete 5 study contacts in addition to completing daily diaries for the first 4 weeks of the study. Participation will last 3 months.
Varenicline is a well-established medication that helps smokers quit. If participants are in the group that receives varenicline, it may help them too. But they are not required to use it, and it is completely up to them to use as they wish. Side effects from taking varenicline might include insomnia, headache, or nausea. Some individuals report negative changes in mood. Most smokers who use varenicline do not experience these symptoms.
Depression treatment is a core health disparity for Latinos in the U.S. as U.S. Latinos are more likely than non-Hispanic Whites to experience depression, but are less than half as likely as Whites to receive evidence-based care for depressive symptomatology. Mobile technologies offer an ideal strategy for meeting the widespread depression treatment needs of U.S. Latinos as recent U.S. population-level data suggests that Latinos adopt smartphones at a rate higher than any other demographic group. The purpose of the proposed project is to develop, test, and refine a Spanish-language mobile application version of brief Behavioral Activation, an idiographic, straightforward, empirically supported treatment for elevated depressive symptoms, for referral by primary care physicians in the service of increasing access to evidence-based treatment for depression for Latinos.